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Abstract
Background: Post-surgical pain impacts many patient outcomes. Ef-
fective pain management increasingly relies on multimodal analgesia 
regimens in which acetaminophen (APAP) is a key component. The 
aim of our study was to examine the impact of oral APAP versus intra-
venous (IV) APAP as a component of post-surgical pain management 
after Cesarean sections and hysterectomies.
Methods: A retrospective analysis of the Cerner HealthFacts® data-
base (from January, 2011 to December, 2015) was conducted to com-
pare outcomes of Cesarean section and hysterectomy surgery patients 
who received oral APAP to those who received IV APAP post-sur-
gically. Length of stay (LOS), daily morphine milligram equivalent 
(MME) consumption, the presence of potential opioid-related adverse 
events (ORADEs), and total pharmacy costs were assessed. Adjusted 
results were derived using inverse probability weighted regression 
adjustment (IPW-RA) estimators based on covariates that included 
demographics, comorbidities, patient clinical characteristics, and hos-
pital characteristics.
Results: The study identified 29,124 Cesarean section patients 
(24,612 oral APAP; 4,512 IV APAP) and 9,767 hysterectomy surgery 
patients (5,586 oral APAP; 4,181 IV APAP). Compared to the oral 
APAP group, the IV APAP group had reductions in adjusted LOS (Ce-
sarean section: -11.7% days (P < 0.001), hysterectomy: -11.8% days 
(P = 0.005)), lowered adjusted daily MME consumption from day 0 
to day 3 (Cesarean section: -1.6 mg (P < 0.001), hysterectomy: -1.7 
mg (P = 0.014)), and reduced risk of ORADEs for Cesarean sections 
(relative risk of 0.45, P < 0.001). Total pharmacy costs were not sig-
nificantly different between the two APAP groups.
Conclusions: Post-surgical pain managed with IV APAP in patients 
undergoing Cesarean section or hysterectomy was associated with 
shorter LOS, reduced risk of ORADEs, and lower opioid consump-
tion compared to patients managed with oral APAP, without adversely 
impacting total pharmacy costs.
Keywords: IV acetaminophen; Multimodal analgesia; Cesarean sec-
tion; Hysterectomy; Opioid; Post-surgical pain; Acute pain; Health 
outcomes
Introduction
Post-surgical pain management is the key to successful surgi-
cal recovery [1]. Acute pain impacts short-term and long-term 
post-surgical outcomes since inadequate pain management can 
result in extended hospital length of stay (LOS) and increased 
risk of developing chronic pain [2, 3]. Population-based studies 
suggest that women may be more likely to experience chronic 
pain syndromes, and obstetric and gynecologic surgeries are 
among the most common surgeries in women [4-6].
The most commonly used analgesics for post-surgical 
pain are intravenous (IV) and oral opioids. While effective 
for pain relief, opioids are associated with a variety of costly 
opioid-related adverse events (ORADEs) [7, 8]. Opioid use 
can lead to addiction and abuse [9], and the overprescribing of 
opioids post-surgery is a contributor to the opioid epidemic in 
the United States [10]. Differences in opioid efficacy have also 
been reported between women and men [11, 12], and follow-
ing Cesarean deliveries, additional concerns for postoperative 
pain management arise. For example, although breastfeeding 
while receiving opioid medications is generally permitted [13, 
14], sedation associated with opioid-based analgesia following 
Cesarean sections can disrupt breastfeeding, infant care, and 
mother-infant bonding [15]; while suboptimal pain manage-
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ment or increased sedation may impair the mother’s ambula-
tion, which increases the risk of thromboembolic disease [16].
New guidelines from the American Pain Society (APS), 
the American Society of Anesthesiologists (ASA), and the 
American Society of Regional Anesthesia and Pain Medicine 
(ASRA), as well as other professional societies, strongly recom-
mend the use of multimodal therapies, incorporating non-opi-
oid analgesics as foundational therapies to treat postoperative 
pain [17]. The American College of Obstetricians and Gy-
necologists (ACOG), the Society for Maternal-Fetal Medicine 
(SMFM), and the Academy of Breastfeeding Medicine (ABM) 
have specific guidelines and recommendations for breastfeed-
ing mothers that include maximizing the use of multi-modal 
non-opioid analgesics, such as non-steroidal anti-inflammatory 
drugs (NSAIDs) and acetaminophen (APAP) if feasible and as 
appropriate [18]. Multimodal analgesia (MMA) regimens can 
generally reduce the use of opioids and consequent ORADEs 
[17]. Since most pain is multi-factorial in nature, owing to the 
physiology of pain transmission, the use of combinations of 
analgesics with differing mechanisms of action may also have 
additive or synergistic effects to reduce pain [19-22].
MMA regimens are well-established in guidelines for both 
Cesarean section and hysterectomy surgeries. In both surgi-
cal types, MMA has been associated with reduced hospital 
LOS and decreased opioid use [23-26]. A plethora of medica-
tions are utilized in MMA regimens, including NSAIDs, non-
NSAIDs (e.g. APAP) and GABA analogs (gabapentin, prega-
balin) [20, 21]. However, NSAIDS may be contra-indicated 
when certain comorbidities are present [27].
Oral APAP has been widely used for over 50 years. An intra-
venous (IV) APAP formulation appropriate for post-surgical pa-
tients who cannot take oral drugs due to sedation, nausea, vomit-
ing, or slow gastrointestinal (GI) recovery became available in 
2010. Use of IV APAP has expanded in several surgery types, 
including orthopedic and spine surgeries, but the overall impact 
of IV APAP on post-surgical pain remains relatively unstudied 
in non-clinical trials, real-world conditions, and especially in 
obstetric or gynecologic surgeries [2, 28, 29]. The primary ob-
jective for this retrospective analysis of electronic health records 
(EHR) was to evaluate the clinical and administrative outcomes 
associated with the utilization of oral APAP versus IV APAP in 
women undergoing a Cesarean section or hysterectomy.
Methods
Study design
This retrospective cohort study was conducted using data from 
the Cerner HealthFacts® dataset (Cerner HealthFacts®; Kan-
sas City, MO) from January 1, 2011 to December 31, 2015. 
Cerner HealthFacts® is a large US electronic health database, 
based on patient records across the United States from over 
600 hospitals. Patients receiving oral APAP versus IV APAP 
(verified through the selected National Drug Codes; NDC) 
and medication administration route in a post-surgical setting 
were evaluated. The study was granted an Institutional Review 
Board exemption from Western IRB.
Patients and selection
The patient population was selected using International Clas-
sification of Diseases (ICD)-9-CM and ICD-10-CM codes for 
Cesarean section and hysterectomy surgeries (Fig. 1). Inclu-
sion criteria selected adult patients (≥ 18 years) undergoing 
a qualifying Cesarean or hysterectomy procedure (see Sup-
plementary Table 1, www.jocmr.org), with admission between 
January 1, 2011 and December 31, 2015, and administration of 
either oral APAP or IV APAP during the first 24 h post-surgery 
(day 0) (see medication criteria schematic in Supplementary 
Figure 1, www.jocmr.org). Oral APAP was defined as tablet 
or capsule formulations of APAP. Other formulations, such as 
liquid taken orally or suppositories, were not considered for in-
clusion. Combination APAP medications (e.g. acetaminophen/
dextromethorphan/doxylamine  succinate/pseudoephedrine 
HCl) were not regarded as oral APAP for inclusion purposes. 
Exclusion criteria included patients with < 6 months of his-
tory captured in the database prior to the index visit, missing 
information for age or gender, and in-hospital LOS > 90 days. 
The oral APAP and IV APAP cohorts were mutually exclusive. 
Patients in the oral APAP cohort could not have received IV 
Figure 1. Patient selection in OB/GYN patients treated with oral vs. IV 
APAP. The study identified 30,198 unique Cesarean section and hys-
terectomy patients who were treated with oral APAP and 8,693 Ce-
sarean section and hysterectomy patients who were treated with IV 
APAP. IV: intravenous; APAP: acetaminophen; OB/GYN: obstetrics and 
gynecology.
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APAP on days 0 - 3 and vice versa. Patients were excluded 
if they had received either oral or IV APAP on day 4 or after 
(see medication criteria schematic in Supplementary Figure 1, 
www.jocmr.org).
Patient characteristics
Baseline characteristics (e.g. age, gender, race, year of admis-
sion) and chronic comorbidities (based on the definitions of 
Elixhauser) at index admission and study outcomes were col-
lected [30]. The Elixhauser comorbidities were calculated us-
ing the approach from Healthcare Cost and Utilization Project 
(HCUP), Elixhauser Comorbidity Software, Version 3.7 [30]. 
Hospital characteristics (e.g. bed size, urban/rural status, cen-
sus region) at index admission and payer type were collected 
as reported. Additional information about procedure type for 
hysterectomies were incorporated into analytical models as 
open, laparoscopic, total vaginal hysterectomy, and total ab-
dominal hysterectomy.
Table 1.  Demographics and Baseline Characteristics for Cesarean Section Surgery Patients
Variable IV APAP (N = 4,512) % Oral APAP (N= 24,612) %
Age (mean, SD) 30.9 (6.0) 29.6 (5.9)
Imputed BMI (mean, SD) 33.3 (6.8) 33.8 (7.0)
Race
  Caucasian 2,181 48.3% 17,180 69.8%
  African American 1,656 36.7% 3,127 12.7%
  Asian/other 465 10.3% 3,006 12.2%
  Hispanic 54 1.2% 960 3.9%
  Missing/unknown 156 3.5% 339 1.4%
Admission source
  Emergency 1,717 38.1% 109 0.4%
  Healthcare facility 844 18.7% 137 0.6%
  Non-healthcare facility 1,559 34.6% 20,245 82.3%
  Other 56 1.2% 2,170 8.8%
  Unknown 336 7.5% 1,951 7.9%
Admission type
  Emergency 1,785 39.6% 415 1.79%
  Urgent 520 11.5% 3,806 15.5%
  Elective 1,980 43.9% 18,430 74.9%
  Other 4 0.1% 677 2.8%
  Unknown 223 4.9% 1,284 5.2%
Hospital characteristics
  Urban 1,497 33.2% 18,716 76.0%
  Teaching hospital (missing 111 patients) 3,793 84.2% 14,651 59.8%
Bed size
  < 200 345 7.7% 7,282 29.6%
  200 to 299 618 13.7% 2,991 12.2%
  300 to 499 831 18.4% 7,540 30.6%
  500+ 2,718 60.2% 6,799 27.6%
Census region
  Midwest 490 10.9% 6,977 28.4%
  Northeast 2,852 63.2% 8,448 34.3%
  South 739 16.4% 5,970 24.3%
  West 431 9.6% 3,217 13.1%
A total of 29,124 Cesarean section surgery patients were analyzed. IV: intravenous; APAP: acetaminophen; SD: standard deviation; BMI: body mass 
index.
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Study outcomes
Study outcomes included length of hospital stay, presence of 
ORADEs, total daily opioid consumption (i.e. morphine (mg) 
equivalent; MME) and total pharmacy cost. Opioid consump-
tion was calculated using the amounts administered to the pa-
tient, while taking into account any doses that were returned to 
the hospital pharmacy unused. The conversion to MME was 
performed as previously described [31, 32]. For outpatients, 
total, per patient, pharmacy cost was calculated by summing 
unit costs for all medications that were dispensed (unit cost 
represent cost per medication package), and for inpatients, it 
was calculated by summing unit cost of the medication multi-
plied by the number of medication units that were charged to 
the pharmacy (unit cost represents cost per unit). Missing body 
mass index (BMI) values were imputed with a univariate im-
putation sampling method from a regression model of known 
covariates [33]. To minimize the effect of outliers, total phar-
macy costs were Winsorized at the 2.5% level, which means 
that values above the 97.5th percentile were set to the 97.5th 
percentile value and values below the 2.5th percentile were set 
to the 2.5th percentile value. Total morphine equivalent dosing 
had the following constraints to be deemed valid: No 4-day 
total from Day 0 to Day 3 could exceed 800 mg MME and 
each day after Day 0 could have no more than 200 mg MME.
Statistical analysis
The Cesarean and hysterectomy patients were analyzed sepa-
rately using multivariable methods. The primary method to 
estimate the impact of IV APAP on the study outcomes (e.g. 
hospital LOS) was inverse probability weighted regression ad-
justment (IPW-RA) with covariates that included patient demo-
graphics, comorbidities, patient admission type (e.g. emergency 
admission), relevant surgical characteristics (e.g. a laparoscopic 
hysterectomy), and prior drug history up to the day of surgery 
[34, 35]. See Supplementary Tables 2, 3 (www.jocmr.org) for 
all variables used for multivariable adjustment. Hospital char-
acteristics (e.g. the number of beds, teaching status, geographic 
location) were also used for adjustment.
As a sensitivity analysis, generalized linear models (GLM) 
estimated the effect of IV APAP on the outcomes and were used 
with the same covariates that were used to estimate the pro-
pensities in the IPW-RA model. For continuous outcomes (e.g. 
LOS) a logarithmic link and a gamma distribution were used in 
the regression models. When the outcomes were binary, logistic 
regression models were utilized. Odds ratios (ORs) were con-
verted to risk ratios (relative risks (RRs)) [36]. All GLM models 
used robust, Huber-White standard error estimators, clustered 
at the hospital level to account for potential serial correlation of 
patient outcomes among patients treated in the same hospital.
Results
We identified 38,891 patients, with 9,767 (25.1%) undergoing 
hysterectomies and 29,124 (74.9%) patients undergoing Cesar-
ean section surgery (Tables 1, 2). Overall, 8,693 (22.4%) of all 
Cesarean section and hysterectomy surgical patients received 
IV APAP (Tables 1, 2). However, the proportion varied by sur-
gical type, with 15.5% of the Cesarean patients and 42.8% of 
hysterectomy patients receiving IV APAP (P < 0.001).
Mean ages within surgical categories were similar between 
the oral and IV APAP groups (Cesarean mean age = 29.6 vs. 
30.9 years; hysterectomy mean age = 47.1 vs. 47.4 years) (Ta-
bles 1, 2). The majority of hysterectomy patients (90.5% of oral 
APAP and 64.3% of IV APAP) were treated at urban facilities. 
In contrast, 76.0% of Cesarean section patients in the oral APAP 
cohorts were treated at urban facilities and only 33.2% of the 
IV APAP cohorts were treated at urban facilities. Regardless of 
procedure type (Cesarean section or hysterectomy) or APAP co-
hort (oral or IV), the majority of patients were treated at teaching 
hospitals, with a greater percentage of IV APAP cohorts treated 
at a teaching hospital versus the oral APAP cohorts.
Adjusted results (see (Supplementary Table 4, www.jocmr.
org) for unadjusted outcomes) were derived using IPW-RA esti-
mators based on covariates that included demographics, comor-
bidities, patient clinical characteristics, and hospital characteris-
tics. In the IPW-RA analyses (Table 3), Cesarean section patients 
receiving IV APAP (versus oral APAP) showed an 11.7% shorter 
LOS. In the IV APAP cohort, the total (marginal) mean adjusted 
LOS was 3.40 days (95% CI 3.29, 3.51) for IV APAP versus 3.85 
days (95% CI 3.60, 4.10) for oral APAP. This 0.45 day shorter 
LOS for IV APAP patients (95% CI -0.72, -0.17) was statistically 
significant (P < 0.001). Similarly, in patients undergoing hyster-
ectomies, IV APAP was associated with an 11.8% shorter LOS, 
with a total adjusted 2.01 days (95% CI 1.89, 2.13) for IV APAP 
versus LOS of 2.28 days (95% CI 1.14, 2.43) for oral APAP. This 
0.27 day shorter LOS for IV APAP patients (95% CI -0.46, -0.08) 
was also statistically significant (P < 0.001). The results in the 
GLM sensitivity analyses (Table 3) showed similar reductions in 
LOS associated with the receipt of IV APAP.
Total MME consumption per day observed from Day 0 
to Day 3 was statistically significantly lower for IV APAP 
patients in both Cesarean section and hysterectomy surgeries 
(-1.6 mg; 95% CI -2.5, -0.8; P < 0.001 for Cesarean section and 
-1.7 mg; 95% CI -3.1, -0.3; P < 0.014 for hysterectomy) (Table 
3). However, these differences in total MME consumption per 
day were not significantly different by APAP route in the GLM 
sensitivity analysis for either surgery type.
IV APAP was associated with fewer potential ORADEs 
[37] than oral APAP in Cesarean section surgeries (relative risk 
= 0.45; 95% CI 0.26, 0.78; P < 0.001). However, there was no 
significant association between the route of APAP administra-
tion and the adjusted risk of potential ORADEs in hysterec-
tomy surgeries (relative risk = 1.09; 95% CI 0.77, 1.41; P = 
0.57). The findings in the GLM sensitivity analyses were also 
concordant, with significant risk reduction for Cesarean sec-
tion, and no significant association for hysterectomy.
IV APAP and oral APAP showed no significant difference 
in pharmacy costs for hysterectomy patients. The IPW-RA 
model did not converge for Cesarean section patients, possibly 
due to some predictors being uncommon but correlated with 
both treatment and costs. Moreover, total pharmacy costs were 
not significantly different for IV APAP and oral APAP in either 
surgery in the GLM sensitivity analysis. We also examined 
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other known cost drivers, including 90-day readmissions, ICU 
admissions and mortality. ICU admissions showed no signifi-
cant differences between IV APAP and oral APAP use in both 
surgery types and the other outcomes were too rare to model 
reliably in these populations (data not reported).
Discussion
Using a large, multi-center, retrospective database, we dem-
onstrated that IV APAP use is associated with significantly 
shorter LOS (by approximately 12%) in Cesarean section and 
hysterectomy patients when compared to oral APAP. This anal-
ysis is one of the first to assess the clinical outcomes and costs 
of oral APAP versus IV APAP from EHRs, from a robust da-
tabase of over 600 hospitals and over 62 million patients. Our 
study focused on Cesarean sections and hysterectomies, where 
reductions in LOS may be most impactful for hospital costs 
and resources, given that these patients generally have consist-
ent LOS, with less variation when compared to other surgeries 
Table 2.  Demographics and Baseline Characteristics for Hysterectomy Surgery Patients
Variable IV APAP (N = 4,181) % Oral APAP (N = 5,586) %
Age (mean, SD) 47.4 (12.0) 47.1 (11.5)
Imputed BMI (mean, SD) 30.9 (7.7) 30.8 (7.4)
Race
  Caucasian 2,833 67.8% 4,013 71.8%
  African American 1,009 24.1% 1,069 19.1%
  Asian/other 265 6.3% 369 6.6%
  Hispanic 18 0.4% 79 1.4%
  Missing/unknown 56 1.3% 56 1.0%
Admission source
  Emergency 31 0.7% 11 0.2%
  Healthcare facility 10 0.2% 10 0.2%
  Non-healthcare facility 3,448 82.5% 4,939 88.4%
  Other 141 3.4% 95 1.7%
  Unknown 246 5.9% 531 9.5%
Admission type
  Emergency 165 4.0% 136 2.4%
  Urgent 56 1.3% 149 2.7%
  Elective 3,833 91.7% 5,213 93.3%
  Other 85 2.0% 2 0.1%
  Unknown 42 1.0% 86 1.5%
Hospital characteristics
  Urban 2,690 64.3% 5,056 90.5%
  Teaching hospital (22 patients missing) 2,962 71.2% 3,317 59.4%
Bed size
  < 200 848 20.3% 1,389 24.9%
  200 to 299 763 18.3% 1,120 20.1%
  300 to 499 1,533 36.7% 1,539 27.6%
  500+ 1,037 24.8% 1,538 27.5%
Census region
  Midwest 957 22.9% 1,298 23.2%
  Northeast 1,046 25.0% 2,047 36.7%
  South 1,507 36.0% 1,668 29.9%
  West 671 16.1% 573 10.3%
A total of 9,767 hysterectomy surgery patients were analyzed. IV: intravenous; APAP: acetaminophen; SD: standard deviation; BMI: body mass index.
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requiring hospitalization. Additionally, research indicates that 
pain management may differ by gender [5], but the potential 
for confounding by sex is eliminated by focusing on Cesarean 
sections and hysterectomies.
A previous claims-based study of Cesarean section and 
hysterectomy surgeries showed significantly less daily opi-
oid use and lower hospitalization costs in patients receiving 
IV APAP as part of MMA versus patients receiving IV opi-
oid-only analgesia in Cesarean section and a non-significant 
trend towards less opioid use and lower cost in hysterectomy; 
however, the claims-based analysis did not show reductions in 
LOS in the IV APAP cohort following adjustment [24]. The 
current study demonstrates statistically significant reductions 
in LOS and opioid consumption for both Cesarean section and 
hysterectomy patients. The LOS reductions approached 12%, 
translating to a reduction of approximately 8 to 12 h, or po-
tentially one nursing shift per day. In the Cesarean group, IV 
APAP patients also had lower risk of developing an ORADE. 
There were no statistically significant differences in total phar-
macy costs between oral APAP and IV APAP, despite cost dif-
ferences between these formulations.
These findings are consistent with prior studies of MMA 
protocols including IV APAP, demonstrating a reduced LOS in 
orthopedic and spine surgery patients [38, 39]. Retrospective 
studies in orthopedic and other surgery types have found simi-
lar associations [24, 40-42]. MMA is thought to improve surgi-
cal outcomes by reducing opioid dosing, resulting in decreased 
ORADEs and complications, and creating synergies that result 
in pain reductions. APAP exerts its effects in the central nerv-
ous system, and versus oral APAP, IV APAP has a faster T max 
and a higher C max, with pharmacokinetics that achieve great-
er concentration in cerebrospinal fluid, suggesting better anal-
gesia from this formulation [43, 44]. Our results support these 
findings and suggest that IV APAP use may be cost-effective 
for Cesarean section and hysterectomy surgeries through the 
reduction of LOS, opioid consumption, and ORADEs.
Other studies have also found that MMA following Cesar-
ean sections or hysterectomies can help to minimize/manage 
postoperative pain and drive positive clinical outcomes [26, 45]. 
MMA after Cesarean section has been shown to provide better 
clinical outcomes with less reliance on opioid pain medications 
[45, 46]. Supplemental uses of non-opioid medications have 
been associated with superior pain relief, improved analgesia, 
and opioid sparing (reduced morphine consumption) [47, 48].
Similar to Cesarean section surgeries, MMA in hysterecto-
my surgeries is associated with reduced hospital LOS follow-
ing both open abdominal surgeries and minimally invasive/
laparoscopic surgeries [23, 26]. Likewise, MMA in hysterecto-
my surgeries decreased total opioid utilization perioperatively 
on postoperative days 1 and 2 [25]. Furthermore, this reduced 
opioid consumption via MMA does not reduce the efficacy of 
pain relief [25].
While our results demonstrate an association between 
IV APAP and shorter LOS, further studies should examine 
other aspects of efficacy, including pain reduction. Addition-
ally, multimodal therapy including IV APAP may help to re-
duce sedation associated with opioids to promote mother-baby 
bonding, caretaking, breast-feeding, and ambulation [15, 16]. 
Furthermore, reducing the LOS and ORADEs could also help Ta
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mothers return to their families earlier and perform their daily 
activities normally. Therefore, using IV APAP in Cesarean sec-
tion surgeries may benefit both the mother and the newborn 
infant.
Using IV APAP in a multimodal pain management ap-
proach after Cesarean sections or hysterectomies may also re-
duce the risk of postoperative opioid-related complications by 
decreasing the amount of opioids used. In fact, a previous study 
found that, compared with IV opioid-only analgesia, managing 
pain after Cesarean sections or hysterectomies with the addition 
of IV APAP decreased both opioid use and hospitalization costs 
[24].
The study’s strengths include the large, multi-center na-
ture of the database and the breadth of variables used to adjust 
for potential confounding. Another strength is the statistical 
methodology; IPW-RA is a more sophisticated method than 
related approaches like propensity score matching. With IPW-
RA, one model is used to derive probabilities (propensities) for 
treatment and another uses these probabilities in a weighted re-
gression model to estimate average treatment effects. Because 
IPW-RA estimators are doubly robust, only one of the two 
models must be correctly specified for the IPW-RA estimator 
to be consistent. IPW-RA models may not produce a solution 
with a large number of rare predictors. To address this possibil-
ity, we used a more traditional regression model approach as a 
sensitivity analysis and found generally similar findings.
One limitation of this study is that these findings may not 
be generalizable to Cesarean or hysterectomy patients that 
differ substantially from those observed in the Cerner Health-
Facts database. It is also unknown how oral APAP versus IV 
APAP correlates with hospital LOS in other surgical popula-
tions. Another study limitation is unmeasured confounding. 
Laboratory results and acuity measures were not analyzed, and 
the chronic comorbidities defined by Elixhauser were not de-
veloped specifically for the Cesarean section and hysterectomy 
populations [30]. Specific Cesarean section and hysterectomy 
variables like pre-eclampsia were not available for this analy-
sis. Nevertheless, a large number of covariates were used for 
multivariable adjustment. Finally, total cost data could not be 
reported, as the percentage of patients missing unadjusted data 
was too high.
Overall, this study provides further evidence supporting 
the preferential use of IV APAP as part of MMA regimens in 
Cesarean section and hysterectomy surgeries by demonstrating 
decreases in LOS, opioid consumption, and ORADE rate.
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